Following older adults with blood cancers who receive CAR-T therapy
Follows adults 60 and older with lymphoma or myeloma receiving CAR-T cell therapy.
Plain-language title generated from the registry record
Registry title: Study of CAR-T Therapy in Older Patients
Key facts
- Where
- New York, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 60 or older with lymphoma or a plasma cell disorder that came back or did not respond, who are getting a commercial CAR T-cell product.
- Age
- 60 years or older.
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory (came back or did not respond to treatment) lymphoid malignancy or plasma cell disorder, confirmed by pathology.
- Earlier treatment
- Must be receiving a commercial CAR T-cell product. Must not have had any earlier commercial or investigational CAR T therapy.
- Biomarker or test result
- One group (cohort 4 only) needs a MoCA (memory and thinking test) score below 26 out of 30 at the geriatric visit before CAR T-cell treatment.
Main reasons for not taking part
- Any earlier commercial or investigational CAR T therapy
- Cohort 1 only: major psychiatric disorder, such as major depression, bipolar disorder or schizophrenia
- Cohort 1 only: neurological or neurodegenerative disease, or head injury with loss of consciousness over 60 minutes
- Cohort 1 only: current or past substance abuse
- Cohort 4 only: history of central nervous system (CNS) disease
Read by machine on 9 November 2026.
Where in United States
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT04300998
- Record updated
- 7 April 2026
- Original description
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.Read full original descriptionShow less
Observational Study of Commercial Chimeric Antigen Receptor T-cell (CAR T) Therapy in Older Patients With Hematologic Malignancies and With an Embedded Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluation
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.
Inclusion: are ≥60 years old (all cohorts); have pathologically confirmed, relapsed refractory lymphoid malignancy or plasma cell disorder receiving a commercial CAR T-cell product (all cohorts); able to speak and understand English (cohort 1 and 4 only); have a MoCA score of less than 26 out of 30 during the GA visit by a geriatrician prior to CAR T-cell treatment (cohort 4 only).
Exclusion: Any prior commercial or investigational CAR T therapy (all cohorts); Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report (cohort 1 only); History of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (>60 minutes), as per medical records or patient report (cohort 1 only); Current ongoing substance abuse and/or history of substance abuse, as per medical records or patient report (cohort 1 only); History of CNS disease (cohort 4 only).